Anbio Biotechnology (NNNN) Common Equity (2023 - 2025)

Anbio Biotechnology's Common Equity history runs 3 years deep, the most recent figure standing at $30.2 million for Q4 2025.

• In Q4 2025, Common Equity rose 75.41% year-over-year to $30.2 million; the TTM figure through Dec 2025 stood at $30.2 million (up 75.41% YoY), while the FY2025 annual figure was $30.2 million, up 75.41% from the prior year.
• Common Equity was $30.2 million for Q4 2025 at Anbio Biotechnology, down from $27549.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $27549.5 billion in Q2 2025 to a low of $14.8 million in Q4 2023.
• Historically, Common Equity has averaged $6887.4 billion across 3 years, with a median of $23.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity grew 16.01% in 2024, then soared 75.41% in 2025.
• A 3-year view of Common Equity shows it stood at $14.8 million in 2023, then advanced by 16.01% to $17.2 million in 2024, then jumped by 75.41% to $30.2 million in 2025.
• The last three Common Equity figures came in at $30.2 million (Q4 2025), $27549.5 billion (Q2 2025), and $17.2 million (Q4 2024), per Business Quant data.